Abstract

Duchenne muscular dystrophy (DMD) is a devastating disease that dramatically decreases the lifespan and abilities of affected young people. The primary molecular cause of the disease is the absence of functional dystrophin protein, which is critical to proper muscle function. Those with DMD vary in disease presentation and dystrophin mutation; the same causal mutation may be associated with drastically different levels of disease severity. Also contributing to this variation are the influences of additional modifying genes and/or changes in functional elements governing such modifiers. This genetic heterogeneity complicates the efficacy of treatment methods and to date medical interventions are limited to treating symptoms. Animal models of DMD have been instrumental in teasing out the intricacies of DMD disease and hold great promise for advancing knowledge of its variable presentation and treatment. This review addresses the utility of comparative genomics in elucidating the complex background behind phenotypic variation in a canine model of DMD, Golden Retriever muscular dystrophy (GRMD). This knowledge can be exploited in the development of improved, more personalized treatments for DMD patients, such as therapies that can be tailor-matched to the disease course and genomic background of individual patients.

Highlights

  • Duchenne muscular dystrophy (DMD) is a lethal Xlinked disease in humans characterized by the absence of dystrophin protein, which leads to progressive muscle weakness, respiratory insufficiency, and cardiomyopathy [1]

  • A similar condition, Becker muscular dystrophy (BMD), is caused by mutation of the DMD gene; unlike DMD, the reading frame remains intact in BMD patients

  • This review summarizes present knowledge about the genomic variations underlying the phenotypic variation seen in DMD and its animal models – golden retriever muscular dystrophy (GRMD)

Read more

Summary

Introduction

Duchenne muscular dystrophy (DMD) is a lethal Xlinked disease in humans characterized by the absence of dystrophin protein, which leads to progressive muscle weakness, respiratory insufficiency, and cardiomyopathy [1]. Even though the DMD gene has been identified as the mutated locus causal for Duchenne muscular dystrophy [1], multiple other loci are suspected to be involved in the phenotypic variability in DMD patients, perhaps via epistatic interactions [41]. Animal models of DMD provide insight into phenotypic and genotypic variation in the disease and the molecular basis for such diversity, suggesting therapeutic targets for the development of personalized treatments.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.